



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Comparative Study of Self-mutilation and Suicide between Opioid and Synthetic Cannabinoid Use Dependent Male Patients

Thesis

For Partial Fulfillment of Master Degree
in Neuropsychiatry

By

Hanan Ahmed Mansour El-Sayed

M.B.B.CH, Faculty of Medicine, Cairo University

Under Supervision of

Prof. Dr. Amany Haroun El Rasheed Abdel Hameed

Professor of Psychiatry

Faculty of Medicine -Ain Shams University

Prof. Dr. Mahmoud Mamdouh ElHabiby

Professor of Psychiatry

Faculty of Medicine -Ain Shams University

Ass. Prof. Dr. Hanan Hany ElRassas

Assistant Professor of Psychiatry

Faculty of Medicine -Ain Shams University

Faculty of Medicine
Ain Shams University
2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَحَانَكَ لَا يَهْتَمُّ لَنَا
إِلَّا مَا عَلِمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٢٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Amany Haroun El Rasheed Abdel Hameed**, Professor of Psychiatry, Faculty of Medicine -Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Mahmoud Mamdouh ElHabiby**, Professor of Psychiatry, Faculty of Medicine -Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Ass. Prof. Dr. Hanan Hany ElRasas**, Assistant Professor of Psychiatry, Faculty of Medicine -Ain Shams University, for her great help, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Hanan Ahmed Mansour ElSayed

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iv
List of Abbreviations	vi
Introduction.....	1
Aim of the Work.....	5
Reivew of Literature	
Substance use disorder.....	6
Opioids Use Disorder And Their Correlation With Suicide And Self-Mutilation.....	21
Synthetic Cannabinoids Use Disorder And Their Correlation With Suicide And Self-Mutilation.....	42
Suicide And Self-Mutilation.....	52
Patients and Methods	90
Results.....	101
Discussion.....	148
Summary.....	169
Conclusion	177
Strengths and Limitations	178
Recommendations.....	179
Appendices	181
References.....	247
Arabic Summary	---

List of Tables

Table No.	Title	Page No.
Table (1):	Comparison between the two studied groups regarding Socio-demographic data	104
Table (2):	The main substance used in both studied groups regarding National Drugs Observatory File	107
Table (3):	Comparison between the two studied groups regarding other substances	109
Table (4):	Comparison between the two studied groups regarding age of onset of smoking Nicotine	111
Table (5):	Comparison between the two studied groups regarding age of onset of substance use	113
Table (6):	Comparison of family history of substance use disorder between the two studied groups	113
Table (7):	Comparison between the two studied groups regarding previous medical help seeking and number of admissions	114
Table (8):	Comparison between the two studied groups regarding number of relapses	115
Table (9):	Comparison between the two studied groups regarding Medical history	116
Table (10):	Comparison between the two studied groups regarding current psychopharmacological agents	118
Table (11):	Addiction Severity Index in the two studied groups	121
Table (12):	Comparison between the two studied groups regarding Columbia–Suicide Severity Rating Scale (C-SSRS) (Ideation and Behavior).....	124
Table (13):	Comparison between the two studied groups regarding Columbia–Suicide Severity Rating Scale (C-SSRS).....	125
Table (14):	Comparison between the two studied groups regarding Self-Punishment Questionnaire	127

List of Tables (cont...)

Table No.	Title	Page No.
Table (15):	Comparison between the two studied groups regarding Self-Punishment Questionnaire main domains	129
Table (16):	Comparison between the two studied groups regarding Mini- International Neuropsychiatric Interview (MINI) scale.....	131
Table (17):	Correlation between Self-Punishment Questionnaire and Colombia Suicide Severity Rating Scale in Synthetic Cannabinoids (SCs) group	133
Table (18):	Correlation between Self-Punishment Questionnaire and Colombia Suicide Severity Rating Scale in opioids group.....	134
Table (19):	Correlation between Columbia–Suicide Severity Rating Scale (Suicide Ideation) and Socio-demographic data in Synthetic Cannabinoids (SCs) group	135
Table (20):	Correlation between Columbia–Suicide Severity Rating Scale (C-SSRS) (Suicide Behavior) and Socio-demographic data in Synthetic Cannabinoids (SCs) group	136
Table (21):	Correlation between Columbia–Suicide Severity Rating Scale (Suicide Ideation) and Socio-demographic data in opioids group	137
Table (22):	Correlation between Columbia–Suicide Severity Rating Scale (Suicide Behavior) with Socio-demographic data in opioids group	138
Table (23):	Correlation between Self-Punishment Questionnaire and Socio-demographic data in Synthetic Cannabinoids (SCs) group	139
Table (24):	Correlation between Self-Punishment Questionnaire and Socio demographic data in opioids group	140

List of Tables (cont...)

Table No.	Title	Page No.
Table (25):	Correlation between Columbia–Suicide Severity Rating Scale (Suicide Ideation) and Addiction Severity Index in synthetic cannabinoids (SCs) group	141
Table (26):	Correlation between Columbia–Suicide Severity Rating Scale (Suicide Behavior) and Addiction Severity Index in synthetic cannabinoids (SCs) group	142
Table (27):	Correlation between Columbia–Suicide Severity Rating Scale (Suicide Ideation) and Addiction Severity Index in opioids group	143
Table (28):	Correlation between Columbia–Suicide Severity Rating Scale (Suicide Behavior) and Addiction Severity Index in opioids group	144
Table (29):	Correlation between Self-Punishment Questionnaire and Addiction Severity Index in synthetic cannabinoids (SCs) group	145
Table (30):	Correlation between Self-punishment Questionnaire and Addiction Severity Index in opioids group	146

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Areas in the human brain which are important in addiction.....	11
Figure (2):	Conceptual framework for neurobiological bases of the transition to substance use disorders.	13
Figure (3):	Model of the progression from misuse of opioids toward moderate or severe OUD (i.e., opioid addiction)	25
Figure (4):	Global variations in suicide rates	54
Figure (5):	Suicide rates by gender from 2000 to 2015.	54
Figure (6):	Suicide rates in selected countries from 2000 to 2015.....	55
Figure (7):	The Bio-psychosocial model of suicide risk.	57
Figure (8):	Neurobiological changes in suicidal behavior	65
Figure (9):	Approaches for preventing suicide	68
Figure (10):	Age in the two studied groups.....	106
Figure (11):	Age strata in the two studied groups.....	106
Figure (12):	Main substances in the two studied groups.....	108
Figure (13):	Other substances usage in the two studied groups	110
Figure (14):	Comparison between the two studied groups regarding age of onset of smoking nicotine	112
Figure (15):	Comparison between the two studied groups regarding number of relapses.....	115
Figure (16):	Comparison between the two studied groups regarding (HIV-HCV –Seizures)	117
Figure (17):	Current psychopharmacological agents between the two studied groups	119
Figure (18):	Comparison between the two studied groups regarding Columbia–Suicide Severity Rating Scale (suicidal ideation and suicidal behavior)	124

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (19):	Comparison between the two studied groups regarding Columbia–Suicide Severity Rating Scale (C-SSRS).....	126
Figure (20):	Self-Punishment Questionnaire between the two studied groups	128
Figure (21):	Self-Punishment Questionnaire in the two studied groups	128
Figure (22):	The main domains of Self-Punishment Questionnaire in the two studied groups	130

List of Abbreviations

Abb.	Full term
<i>ACTH</i>	<i>Adrenocorticotrophic hormone</i>
<i>ADHD</i>	<i>Attention-deficit hyperactivity disorder</i>
<i>BPD</i>	<i>Borderline personality disorder</i>
<i>CAREs</i>	<i>Community-based addiction rehabilitation electronic system</i>
<i>CBT</i>	<i>Cognitive behavioral therapy</i>
<i>CM</i>	<i>Contingency Management</i>
<i>CNS</i>	<i>Central nervous system</i>
<i>CR</i>	<i>Cognitive restructuring</i>
<i>CRF</i>	<i>Corticotropin-releasing factor</i>
<i>CRP</i>	<i>C-reactive protein</i>
<i>C-SSRS</i>	<i>Columbia Suicide Severity Rating Scale</i>
<i>CT</i>	<i>Cognitive therapy</i>
<i>DBT</i>	<i>Dialectic behavioral therapy</i>
<i>DD</i>	<i>Dual diagnosis</i>
<i>DEA</i>	<i>Drug Enforcement Administration</i>
<i>ED</i>	<i>Emergency department</i>
<i>ELA</i>	<i>Early life adversity</i>
<i>EMA</i>	<i>Ecological momentary assessment</i>
<i>EVA</i>	<i>Ethylene vinyl acetate</i>
<i>HAT</i>	<i>Heroin assisted treatment centers</i>
<i>HPA</i>	<i>Hypothalamic Pituitary Adrenal axis</i>
<i>HS</i>	<i>Highly significant</i>
<i>HT</i>	<i>Hopelessness theory</i>
<i>IL</i>	<i>Interleukin</i>
<i>IQR</i>	<i>Interquartile range</i>
<i>LRAMP</i>	<i>Linehan Suicide Risk Assessment and Management Protocol</i>
<i>MDD</i>	<i>Major depressive disorder</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>DSH</i>	<i>Deliberate self-harm</i>
<i>IBM</i>	<i>International Business Machines</i>
<i>MINI</i>	<i>Mini-International Neuropsychiatric Interview</i>
<i>MMTPs</i>	<i>Methadone maintenance treatment programs</i>
<i>NA</i>	<i>Narcotics Anonymous</i>
<i>NS</i>	<i>Non significant</i>
<i>NS-SDV</i>	<i>non-suicidal self-directed violence</i>
<i>NSSI</i>	<i>non-suicidal self-injury</i>
<i>ODU</i>	<i>Opioid use disorder</i>
<i>S</i>	<i>Significant</i>
<i>SA</i>	<i>Suicidal attempt</i>
<i>SC</i>	<i>Synthetic cannabinoids</i>
<i>SMI</i>	<i>Severe mental illness</i>
<i>SPI</i>	<i>Safety planning intervention</i>
<i>SPI</i>	<i>Safety planning intervention</i>
<i>SPSS</i>	<i>Statistical Package for the Social Sciences</i>
<i>SSRIs</i>	<i>selective serotonin reuptake inhibitors</i>
<i>SUD</i>	<i>Substance use disorder</i>
<i>THC</i>	<i>Tetrahydrocannabinol</i>
<i>US</i>	<i>United States</i>
<i>WHO</i>	<i>World Health Organization</i>

INTRODUCTION

Substance use disorder (SUD) is defined as; Prolonged, repeated use of substances at high doses and/or high frequencies (quantity/frequency thresholds vary across substances) which produce a separate, independent, diagnosable illness that impairs health and function and may require special treatment (*McLellan 2017*). SUD is considered as a way of self-harm (*Breet et al., 2017*).

Cannabinoids are the most commonly abused substances in the world. In Egypt, the Anti-Narcotic General Administration showed that the narcotics problem costs the Egyptian economy approximately 800 million dollars annually (*Yassa et al., 2010*). Synthetic Cannabinoids (SC) abuse is a significant public health and safety problem, resulting in many emergency department visits and fatalities (*Huestis and Diao 2017*).

The widespread over-the-counter availability of these products made these compounds the 2nd most common frequently used recreational drug after marijuana in teenagers and young adults (*Mansour et al., 2020*). Chronic use of SCs has been associated with serious Psychiatric and medical conditions and even death (*Cohen et al., 2018*). SCs products may potentially lead to suicidal ideation and self-harm behaviors amongst many other psychiatric symptoms. The long-term risks are still unclear, but aggression, self-harm, and